Clinical trials: Acute Mania
Acute Mania, Bipolar Disorder, Manic
Ziprasidone And Olanzapine's Outcomes In Mania
The purpose of this study is to compare the efficacy and tolerability of ziprasidone versus olanzapine in the treatment of acute mania.
- Trial name
- ZOOM (NCT00329108)
- Testing
- ziprasidone hydrochloride, olanzapine
- Where
- 19 sites in Germany, Greece and 3 more
- Volunteers
- 29 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Mania
A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the treatment of the acute exacerbation of non-organic psychosis of any etiology, including schizophrenia, acute mania, delusional disorder and…
- Conditions
- Schizophrenia, Mania, Delusional Disorder, Acute Exacerbation of Psychosis
- Trial name
- NCT00644800
- Testing
- Ziprasidone
- Where
- 8 sites in Brazil
- Volunteers
- 89 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Bipolar I Disorder, Acute Mania
A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder.
This study evaluated the safety and evaluate the safety and tolerability of open-label brexpiprazole (2 - 4 mg/day, with a starting dose of 2 mg/day) for the treatment of adult subjects with bipolar I disorder.
- Trial name
- NCT03287869
- Testing
- Brexpiprazole
- Where
- 73 sites in United States, Bulgaria and 4 more
- Volunteers
- 381 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Acute Bipolar Mania
A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study
The primary objective of this study is to compare the efficacy of Seroquel XR monotherapy compared with Seroquel XR plus lithium in the treatment of acute bipolar mania by evaluation of the changes from baseline in Young Mania…
- Trial name
- STAR (NCT01254721)
- Testing
- Quetiapine fumarate, lithium
- Where
- 5 sites in South Korea
- Volunteers
- 131 people
- Sponsor
- AstraZeneca
Acute Mania in Bipolar Disorder
Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder
To compare the efficacy and safety of quetiapine fumarate given as mono-therapy or adjunct therapy to lithium in the treatment of patients with acute mania in bipolar disorder.
- Trial name
- MANIA (NCT00672490)
- Testing
- Quetiapine Fumarate, Lithium
- Where
- 16 sites in China
- Volunteers
- 376 people
- Sponsor
- AstraZeneca
Acute Mania
Adult Bipolar Mania
The purpose of this study is to determine if lithium 600-1800 mg/day is effective when added to quetiapine fumarate extended release (quetiapine XR or SEROQUEL® XR) 400-800 mg/day in treating acute mania and if so, how it…
- Trial name
- NCT00931723
- Testing
- Quetiapine fumarate XR, Lithium
- Where
- 65 sites in Belgium, Bulgaria and 7 more
- Volunteers
- 356 people
- Sponsor
- AstraZeneca
Acute Bipolar Mania
Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy
The primary objective of this study is to evaluate the broad clinical benefit of dosing Seroquel XR with flexible in the treatment of acute bipolar mania patients with partial response to existing therapy.
- Trial name
- RELEASE (NCT01128114)
- Testing
- Quetiapine fumarate (Seroquel XR)
- Where
- 11 sites in South Korea
- Volunteers
- 32 people
- Sponsor
- AstraZeneca